Adia Med Inc. ADIA OTC · Healthcare · United States
$0.13 +0.00% +$0.00
Summary
16 / 100 · Bulios Score
What speaks for it
- It has no debt and holds $1.14M in cash.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Revenue (USD)
Diluted EPS (USD)
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $394.5K.
Profitability in detailIs it financially healthy?
YesIt has no debt. The debt score is low because of the debt-to-equity ratio.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Biologics 99%
- Services 0.8%
By region
The company reports no revenue by region.
Biologics brings in 99% of revenue.
Segments in detail